2024年11月7日,阿霞制药公司(Amphastar Pharmaceuticals,股票代码:AMPH)股价大幅下跌13.52%,引发市场关注。
公司此前披露的2024财年第三季度财报显示,营收及利润均未达分析师预期,这被认为是导致股价重挫的主因。具体来看,阿霞制药第三季度调整后每股收益为0.96美元,低于分析师平均预期的0.99美元;营收同比增长5.9%至1.91亿美元,但也未达预期的1.95亿美元。
值得注意的是,过去三个月内,分析师对阿霞制药未来盈利预期有所下调,平均预期下降约2.8%。不过他们目前仍给予该股"买入"的评级,预计公司长期业绩有望好转。阿霞制药今年迄今股价累计下跌16.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.